期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?
1
作者 Suzan Samir Elsharkawy Mohamed abd elrheem samia abd elrheem 《Open Journal of Obstetrics and Gynecology》 2021年第2期146-161,共16页
Tumor infiltrating lymphocytes (TILs) are used in evaluating the prognosis and determining treatment of different types of cancer with variable degrees of success. The usage of checkpoint inhibitor immunotherapy as a ... Tumor infiltrating lymphocytes (TILs) are used in evaluating the prognosis and determining treatment of different types of cancer with variable degrees of success. The usage of checkpoint inhibitor immunotherapy as a treatment variety for cancer and Adoptive cell therapy is associated with many complications, severe side effects and high expenses. Recently, in a limited number of metastatic GIT and breast cancers, the identification of T-cell specific against so-called tumor neo-antigens and Adoptive transfer of those lymphocytes resulted in some improvement. In 2020, Detection of a T cell receptor (TCR) in a T cell clone that recognized and killed most human cancer cell lines in vitro via the monomorphic MHC class I-related protein MR1, offers an opportunity for pan-cancer therapy Twenty three years earlier, Moist Heat was used successfully to activate a whole different and new immune response that was able to detect genetic mutation in the affected cancer cells and cured many cases of squamous and basal cell carcinomas. In this commentary review, we aimed to revise the literature for updates of TILs usage in cancer prognosis and treatment. 展开更多
关键词 Tumor Infiltrating Lymphocytes Cancer Checkpoint Inhibitor Adoptive Cell Therapy T Cell Receptor (TCR) Moist Heat Pan-Cancer Therapy Squamous Cell Carcinoma Basal Cell Carcinomas
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部